Loading clinical trials...
Loading clinical trials...
Observational, Post-marketing Renal Safety Surveillance Registry in Subjects With Chronic Hepatitis B (HBV) Infection With Decompensated Liver Disease Receiving Nucleotide/Side Therapy
Conditions
Interventions
Anti-HBV nucleoside/nucleotide therapy
Locations
27
United States
Cedars-Sinai Medical Center for Liver Diseases and Transplantation
Los Angeles, California, United States
University of California Los Angeles
Los Angeles, California, United States
Stanford University
Palo Alto, California, United States
University of California at San Francisco Medical Center
San Francisco, California, United States
Yale University School of Medicine
New Haven, Connecticut, United States
Georgetown University Hospital
Washington D.C., District of Columbia, United States
Start Date
April 26, 2012
Primary Completion Date
April 4, 2017
Completion Date
April 4, 2017
Last Updated
April 24, 2017
NCT07417553
NCT02932150
NCT07024641
NCT05856890
NCT06671093
NCT07275554
Lead Sponsor
Gilead Sciences
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions